Kenneth T. Mills - Jan 1, 2022 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Role
President and CEO, Director
Signature
/s/ Patrick J. Christmas as attorney-in-fact
Stock symbol
RGNX
Transactions as of
Jan 1, 2022
Transactions value $
-$118,897
Form type
4
Date filed
1/4/2022, 08:01 PM
Previous filing
Dec 6, 2021
Next filing
Jan 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGNX Common Stock Tax liability -$119K -3.64K -1.31% $32.70 274K Jan 1, 2022 Direct
transaction RGNX Common Stock Award $0 +35.8K +13.06% $0.00 310K Jan 3, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGNX Stock Option (Right to Buy) Award $0 +170K $0.00 170K Jan 3, 2022 Common Stock 170K $34.31 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026 while the recipient provides continuous service to the Issuer.
F2 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2023 while the optionee provides continuous service to the Issuer.